Results 171 to 180 of about 9,170,294 (335)
Molecular Oncology, EarlyView.A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Things to Know About Working in Solidarity with People in Prison [PDF]
, 2018 Lewin, Michelle L +1 more
core +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Automated assessment of small bowel and colon cleansing in enteroscopy using a convolutional neural network. [PDF]
Endosc Int OpenMarílio Cardoso P +11 more
europepmc +1 more source
A Guide to Parole Preparation In New York State [PDF]
, 2018 Lewin, Michelle L +1 more
core +1 more source
Radical Cross-Linked Albumin Microspheres as Potential Drug Delivery Systems: Preparation and In Vitro Studies [PDF]
, 2005 Francesca Iemma +5 more
openalex +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
New York State Parole Board: Failures in Staffing and Performance [PDF]
, 2018 Parole Preparation Project +1 more
core +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source